Challenges with Solubility and Bioavailability Video, Part 2 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Challenges with Solubility and Bioavailability Video, Part 2

Pharmaceutical Technology

Recorded live at the Interphex 2013 trade show, Rita Peters asks Jeffery C. Basham, vice president, business development: From your experience, do you find that the related project work for solubility/bioavailability enhancement is mostly applied for new drug development or do you see it also driving growth in projects for product lifecycle management, for example, to improve dosing schemes/regimes? Can you provide an example of either case?

Check out the rest of the interview:

Part 1

Part 3


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here